Arterys Custom Case Solution & Analysis

1. Evidence Brief: Business Case Data Researcher

Financial Metrics

• Series A Funding: 12 million dollars led by Emergent Medical Partners.
• Series B Funding: 28 million dollars led by Temasek in 2017.
• Revenue Model: Transitioning from per-scan fees to annual subscription SaaS (Software as a Service) models.
• MRI Scan Time Reduction: Cardiac MRI processing reduced from 60 minutes of manual work to less than 10 minutes using Arterys software.
• Development Cost: High R and D expenditure associated with GPU-based cloud computing and deep learning algorithm training.

Operational Facts

• Technology: 4D Flow Health technology providing non-invasive visualization and quantification of blood flow.
• Platform: Zero-footprint, web-based medical imaging platform accessible via standard internet browsers.
• Regulatory Milestones: Received FDA 510(k) clearance for the first clinical SaaS model utilizing deep learning in 2017.
• Infrastructure: Utilizes Amazon Web Services (AWS) for cloud-based GPU processing to handle massive imaging datasets.
• Geography: Headquartered in San Francisco with clinical partnerships at Stanford University and international deployments.

Stakeholder Positions

• Fabien Beckers (CEO): Advocates for a platform approach where Arterys acts as the backbone for all medical imaging AI.
• Radiologists: Primary users who value time savings and diagnostic accuracy but remain cautious about cloud security and clinical liability.
• Hospital IT Departments: Concerned with HIPAA compliance, data latency, and integration with existing PACS (Picture Archiving and Communication Systems).
• GE Healthcare: Strategic partner and investor, providing a massive distribution channel while simultaneously developing competing internal AI initiatives.

Information Gaps

• Specific churn rates for early hospital adopters are not disclosed.
• Exact customer acquisition costs (CAC) for direct sales versus partnership-led sales.
• Long-term margin impact of AWS cloud costs as scan volumes scale.

2. Strategic Analysis: Market Strategy Consultant

Core Strategic Question

• Should Arterys remain a specialized provider of premium cardiac imaging tools or pivot to become a horizontal AI platform that hosts third-party algorithms?

Structural Analysis

• Value Chain Analysis: The bottleneck in radiology is not image acquisition but interpretation. Arterys shifts the value from the hardware (MRI machines) to the post-processing layer. However, incumbents like Siemens and GE control the point of entry.
• Jobs-to-be-Done: Radiologists need to increase throughput without sacrificing accuracy. Arterys solves the 50-minute manual segmentation problem, turning a specialized task into a routine one.
• Competitive Dynamics: Low barriers to entry for niche AI startups lead to a fragmented market. Arterys faces a choice: compete on clinical depth or platform breadth.

Strategic Options

• Option 1: The Clinical Specialist. Deepen the oncology and neurology pipeline. Focus on proprietary, FDA-cleared algorithms. High margins but slow growth due to clinical trial requirements.
• Option 2: The Open Platform. Open the Arterys infrastructure to third-party developers. Collect a percentage of every scan processed. Rapidly increases the menu of available tools but dilutes the brand and increases liability.
• Option 3: OEM Integration. Embed Arterys software directly into GE and Siemens hardware. Minimal sales cost but high risk of becoming a commodity feature and losing direct customer relationships.

Preliminary Recommendation

Arterys must pursue the Open Platform model. The medical imaging AI market is too fragmented for a single company to build every necessary tool. By providing the regulatory and cloud infrastructure for others, Arterys becomes the indispensable operating system for the radiology suite.

3. Implementation Roadmap: Operations and Implementation Planner

Critical Path

• Month 1-3: Finalize the Marketplace API (Application Programming Interface) to allow third-party algorithms to run on the Arterys cloud viewer.
• Month 4-6: Secure three high-volume oncology or neurology AI partners to anchor the new marketplace.
• Month 7-12: Execute enterprise-wide contracts with five major hospital networks, focusing on the single-platform-multiple-apps value proposition.

Key Constraints

• Data Sovereignty: Many international hospitals prohibit patient data from leaving their borders. Implementation must include regional cloud instances or hybrid-cloud options to bypass these regulatory moats.
• Integration Friction: Replacing a legacy PACS system is a multi-year process. Arterys must function as a seamless overlay rather than a replacement to ensure immediate adoption.

Risk-Adjusted Implementation Strategy

The strategy prioritizes the deployment of a vendor-neutral archive interface. This allows hospitals to keep their existing hardware while using Arterys as the intelligence layer. To mitigate the risk of slow sales cycles, the team will focus on the 20 largest academic medical centers where the volume of complex cases justifies the subscription cost.

4. Executive Review and BLUF

BLUF

Arterys must immediately pivot from a product-centric model to a platform-aggregator strategy. While the cardiac MRI tool is technically superior, it is a feature, not a business. The real value lies in the FDA-cleared, cloud-native infrastructure. By hosting third-party algorithms, Arterys solves the radiology fragmentation problem and creates a defensible position against hardware incumbents. Success requires shifting focus from algorithm development to API excellence and enterprise hospital sales. Move now to capture the platform layer before GE or Siemens can modernize their legacy software stacks.

Dangerous Assumption

The most dangerous assumption is that hospitals will prioritize diagnostic speed over the simplicity of buying from their existing hardware vendors. If incumbents bundle mediocre AI for free, the Arterys superior performance may not justify the friction of a separate procurement process.

Unaddressed Risks

• Cloud Cost Escalation: As scan complexity increases, the computing cost on AWS may erode the margins of the subscription model, especially if third-party developers optimize their code poorly.
• Liability Ambiguity: The analysis does not fully address who is legally responsible when a third-party algorithm hosted on the Arterys platform produces a false negative.

Unconsidered Alternative

The team did not consider a full exit via acquisition to a major tech player like Google or Microsoft. These firms possess the cloud infrastructure Arterys relies on and are currently looking for a clinical-grade entry point into medical imaging. This would provide immediate liquidity and solve the scaling problem.

Verdict

APPROVED FOR LEADERSHIP REVIEW